About Dan

Dan brings to Precision over 15 years of experience developing and leading pharmacy programs in the health plan and PBM industry. Prior to joining Precision, he led Premera Blue Cross’ Drug Management Program where he was responsible for forecasting the impact of high-cost pharmaceuticals and developing utilization management programs to ensure clinically appropriate and cost-effective access. He also provided thought leadership to Premera’s executive teams as well as its independent Pharmacy and Therapeutics Committee. As a recognized expert in value and technology assessment, Dan led the deployment of Premera’s Value-based Formulary as well as managed its independent Value Assessment Committee. Dan has been a contributor to ICER’s Unsupported Price Increase draft protocol as well as authoring and collaborating on several publications including frameworks to assess the clinical and economic value of immuno-oncology.

At Precision, Dan's expertise in health economics has made him a sought after internal resource, client advisor, and commentator on the current state of Preapproval Information Exchange (PIE) and Health Care Economic Information (HCEI) as well as how state and federal policy may use these data and thier impact the underlying economics of the US healthcare environment.

EDUCATION:
BS Pharm, Oregon State University
MS, pharmaceutical policy and economics, University of North Carolina, Chapel Hill

MEMBERSHIPS:
Academy of Managed Care Pharmacy (AMCP)
ISPOR